AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03765359
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets mimic metformin 500 mg tablets and insulin
Trial: NCT02405637
Drug: simulated amniotic fluid 20cc/kg/day enterally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
Trial: NCT01013870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
Trial: NCT00860431
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g/day (3 times a day)
Trial: NCT00289978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients self-administered a fingolimod placebo capsule orally once daily.
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: IV infusion; 0.5 mg/kg Q2W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: IV infusion; 2 mg/kg Q2W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: IV infusion; 5 mg/kg Q2W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: IV infusion; 10 mg/kg Q2W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration : IV infusion, 200 mg Q2W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration : IV infusion, 300 mg Q3W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration : IV infusion, 300 mg Q2W
Trial: NCT04450901
Drug: YBL-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration : IV infusion, 200mg Q2W
Trial: NCT01137565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to AMG 853
Trial: NCT01084759
Drug: Testosterone injection
RxNorm normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
Trial: NCT00004931
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00004931
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01122680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhalation solution
Trial: NCT00501943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02374489
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
Trial: NCT00692237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg (3 capsules/day)
Trial: NCT03779854
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03779854
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00000472
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00683319
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01584557
Drug: placebo or sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT00683319
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00737763
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
Trial: NCT01189812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one time daily for 4 weeks
Trial: NCT01229111
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01229111
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00442039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
Trial: NCT04572841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous
Trial: NCT02384343
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
Trial: NCT03101670
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo oral tablet q.d.
Trial: NCT00666575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
Trial: NCT00063999
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03159442
Drug: AZD8871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
Trial: NCT03159442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for inhalation administered via single dose DPI
Trial: NCT00147537
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles
Trial: NCT00147537
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
Trial: NCT00987935
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT00005596
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005596
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
Trial: NCT00005596
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
Trial: NCT00005596
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22.
Trial: NCT02533154
Drug: Prosicca
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prosicca eyedrops Dosage: on demand Route of administration: topical
Trial: NCT00917020
Drug: Nasal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-Needed during the 14 day Treatment Period
Trial: NCT00917020
Drug: Inactive Placebo Gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02176525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02533154
Drug: Prosicca sine
RxNorm normalized name: tetrahydrozoline hydrochloride Ophthalmic Solution [Eye-Sine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosicca sine eyedrops Dosage: on demand Route of administration: topical
Trial: NCT03760068
Drug: MYL-1601D Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (100 U/mL)
Trial: NCT03760068
Drug: FlexPen NovoLog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (100 U/mL)
Trial: NCT02631694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intake of placebo pill (40 milligram)
Trial: NCT00163852
Drug: Normal saline IV, salt tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01512173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration twice daily
Trial: NCT01871727
Drug: E7777 9 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
Trial: NCT03844412
Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
Trial: NCT03844412
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparison treatment will be an identical-appearing placebo Moisturel™ cream
Trial: NCT03844412
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparison treatment will be an identical-appearing placebo pill
Trial: NCT02294019
Drug: Ibuprofen 400 mg caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 milligram (mg) caplet according to Drug Facts label
Trial: NCT03272165
Drug: MEDI1341
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
Trial: NCT03272165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of placebo matched to MEDI1341.
Trial: NCT02268305
Drug: MSM 1000mg twice a day (6000 mgs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
Trial: NCT03535519
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard of care treatment with methotrexate
Trial: NCT00214526
Drug: Conventional therapy with ICS+LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with ICS+LABA.
Trial: NCT02009449
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration on Day 1 and 2 of every 14 day cycle
Trial: NCT02009449
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Trial: NCT01375985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration
Trial: NCT03559257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT02514967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once per week
Trial: NCT04003389
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT02057666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
Trial: NCT04469530
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube.
Trial: NCT04469530
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
Trial: NCT02096965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive daily dose at 8 AM and at 4 PM.
Trial: NCT01398475
Drug: LY3009104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04566380
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally twice daily
Trial: NCT00507507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match FTC taken once daily
Trial: NCT02194686
Drug: Dummy Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice per day for 12 weeks
Trial: NCT00527878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01671774
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg on d 1 of cycle 1 and cycle 3
Trial: NCT03043989
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 doses of clarithromycin with either Docetaxel or Cabazitaxel
Trial: NCT04029038
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00268398
Drug: oxaliplatin, folinic acid, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
Trial: NCT00268398
Drug: oxaliplatin, irinotecan, folinic acid, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)
Trial: NCT03313960
Drug: Afrezza plus One Drop | Premium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months).
Trial: NCT01654250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03931785
Drug: MD-7246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT03931785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral tablet
Trial: NCT02144246
Drug: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00680836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally two times per day for 14 days
Trial: NCT01531803
Drug: Kedbumin 25%
RxNorm normalized name: Kedbumin 25% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin).
Trial: NCT03881878
Drug: TAHP plus AC and AHP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks
Trial: NCT01034657
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
Trial: NCT03675555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
Trial: NCT03309475
Drug: Psychotropic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual delivered by patient's practitioner
Trial: NCT01450267
Drug: Inhaled Reduced Glutathione
RxNorm normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg, twice daily, 12 months
Trial: NCT01450267
Drug: Physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,13 ml/kg body weight, twice daily, 12 months
Trial: NCT04431778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).
Trial: NCT01436890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet in triple dummy format, Once daily for 12 weeks
Trial: NCT04483219
Drug: TKI ± anti-PD-1 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.
Trial: NCT01104870
Drug: UT-15C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03760640
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01008046
Drug: combined N-acetyl cysteine -CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
Trial: NCT04579419
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 NaCl
Trial: NCT00122863
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01391299
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.